Healthcare

Popular Topics in Healthcare

Explore all subjects

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

Become a GLG Client

All GLG News Analyses Filed Under: Business of Medicine

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

March 6, 2008
Galderma has Strengthened its Position as a Leader in Dermatology

By a GLG Expert Contributor

Analysis of: CollaGenex Pharmaceuticals Agrees to $420M Galderma S.A. Takeover | www.fiercebiotech.com

Galderma has bought out CollaGenex for $420 million. In July 2006, CollaGenex launched Oracea®, the first FDA-approved systemic product for rosacea. CollaGenex is also developing Col-118, a novel product for the treatment of the erythema.

March 5, 2008
Cholesterol lowering: to advertise or not???

By a GLG Expert Contributor

Analysis of: Drug Pitchmen: Actor, Doctor or Pfizer’s Option | www.nytimes.com

"Celebrity" advertisements of percription drugs are disingenuous?

March 5, 2008
Keeping the privacy of health data.

By a GLG Expert Contributor

Analysis of: Google to store patients' health records | news.yahoo.com

1. Internet. 2. Medical records. 3. Privacy.

March 5, 2008
Is close good enough- Heparin Fiasco

By a GLG Expert Contributor

Analysis of: Heparin and other outsourced pharmaceuticals | online.wsj.com

The recent fiasco of Heparin being sold by Baxter International is going to lay the blame of FDA (lack of inspection) and companies from China and India for making poor quality product and shipping it to US sellers. Companies in EU or US who are importing active pharmaceutical ingredients...

March 3, 2008
Just a transition stage

By a GLG Expert Contributor

Analysis of: Google to store patients' health records | news.yahoo.com

Eventually, although not likely in the next ten years, electronic medical records (EMRs) will be the norm; once the interoperability issues are addressed, these records will be sharable across various networks. Until that time, systems such as Google's might serve some purpose. &nb...

March 3, 2008
The Doctor Will Google You Now

By a GLG Expert Contributor

Analysis of: Google to store patients' health records | news.yahoo.com

Google, Inc. (GOOG) this week announced a pilot project with at the Cleveland Clinic to store the information of up to 10,000 patients in a new online electronic health records storage service. Google is not the sole player in the online medical records storage field. Microsoft (MSFT) launched...

March 3, 2008
A merger that makes sense.

By a GLG Expert Contributor

Analysis of: CollaGenex Pharmaceuticals Agrees to $420M Galderma S.A. Takeover | www.fiercebiotech.com

CollaGenex is a smaller, virtual company with 3 marketed products and 1 in development. Galderma is a larger company that markets 4 x as many products, has an international presence, R&D laboratories, and products in development.

Adam Fein, PhD, Founder & President
Pembroke Consulting Inc

March 3, 2008
The Myth of Drug Price Transparency

Analysis of: Report: State Drug Price Sites Flawed | ap.google.com

An interesting new report finds that the drug price comparison web sites run by 10 U.S. states are not always useful or usable. The wide variations in pharmacy prices for a common, high volume generic make me wonder about the efficiency of the pharmacy market and the value of apparent transparency. ...

Steven Fishbane, MD, Chief of Nephrology, Medical Director
Winthrop-University Hospital Inc

March 3, 2008
Amgen, ESA Safety in Oncology, and FDA's ODAC Panel

Analysis of: Anemia Drugs Raise Death Risk for Cancer Patients | blogs.wsj.com

1- This analysis adds to the formalized analysis of the safety literature on ESA use in oncology. 2- Its timing will impact on the FDA CDER ODAC meeting scheduled to review Amgen and Ortho Biotech's ESA drugs.

March 3, 2008
More fuel for the fire

By a GLG Expert Contributor

Analysis of: Study Finds Death Risk From Anemia Drugs | www.nytimes.com

ESA should be used only wher clearly indicated. Otherwise we will see more adverse efffects.